INT-747 is primarily used in the treatment of liver-related conditions due to its role as a selective agonist for the farnesoid X receptor (FXR). It is particularly effective in managing primary biliary cholangitis (PBC), a chronic liver disease, by reducing bile acid accumulation and improving liver function. Additionally, it has shown promise in addressing non-alcoholic steatohepatitis (NASH) by modulating lipid metabolism and reducing inflammation in the liver. Its ability to regulate bile acid synthesis and transport also makes it beneficial in managing cholestatic liver diseases. Ongoing research explores its potential in treating other metabolic and liver disorders.